Corticosteroids in IgA nephropathy: A retrospective analysis from the VALIGA study

Journal of the American Society of Nephrology

Volumn 26, Issue 9, 2015, Pages 2248-2258

  Tesar, Vladimir ^a   Troyanov, Stéphan ^b   Bellur, Shubha ^c   Verhave, Jacobien C ^b   Cook, H Terence ^d   Feehally, John ^e   Roberts, Ian S D ^c   Cattran, Daniel ^f   Coppo, Rosanna ^g  

^a CHARLES UNIVERSITY   (Czech Republic)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^f TORONTO GENERAL HOSPITAL   (Canada)

^g CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ANTIHYPERTENSIVE AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; VALIDATION STUDY; DRUG COMBINATION; FOLLOW UP; GLOMERULONEPHRITIS, IGA; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; YOUNG ADULT;

ADRENAL CORTEX HORMONES; ADULT; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84940779394     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014070697     Document Type: Article

References (31)

1. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP: Predicting renal outcome in IgA nephropathy. J AmSocNephrol 8: 199-207, 1997
2. Berthoux FC, Mohey H, Afiani A: Natural history of primary IgA nephropathy. Semin Nephrol 28: 4-9, 2008
3. Moriyama T, Tanaka K, IwasakiC,Oshima Y,OchiA, KataokaH, ItabashiM, Takei T, Uchida K, Nitta K: Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One 9: e91756, 2014
4. Radhakrishnan J, Cattran DC: The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines-Application to the individual patient. Kidney Int 82: 840-856, 2012
5. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F: Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial. J Am Soc Nephrol 15: 157-163, 2004
6. Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, Roberts IS, Morando L, Camilla R, Tesar V, Lunberg S, Gesualdo L, Emma F, Rollino C, Amore A, Praga M, Feriozzi S, Segoloni G, Pani A, Cancarini G, Durlik M, Moggia E, Mazzucco G, Giannakakis C, Honsova E, Sundelin BB, Di Palma AM, Ferrario F, Gutierrez E, Asunis AM, Barratt J, Tardanico R, Perkowska-Ptasinska A; VALIGA study of the ERA-EDTA Immunonephrology Working Group: Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 86: 828-836, 2014
7. CattranDC, Coppo R,CookHT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, LiPK, Liu ZH,MackinnonB,MezzanoS, Schena FP, Tomino Y,Walker PD, Wang H,Weening JJ, Yoshikawa N, Zhang H;Working Group of the International IgA Nephropathy Network and the Renal Pathology Society: The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 76: 534-545, 2009
8. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F: Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 353: 883-887, 1999
9. Manno C, Torres DD, Rossini M, Pesce F, Schena FP: Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with longtermfollow-up in proteinuric IgA nephropathy.NephrolDial Transplant 24: 3694-3701, 2009
10. Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H: Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial. Am J Kidney Dis 53: 26-32, 2009
11. Reich HN, Troyanov S, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry: Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18: 3177-3183, 2007
12. Hirano K, Kawamura T, Tsuboi N, Okonogi H, Miyazaki Y, Ikeda M, Matsushima M, Hanaoka K, Ogura M, Utsunomiya Y, Hosoya T: The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathy. Clin ExpNephrol 17: 555-562, 2013
13. Pozzi C, Ferrario F, Visciano B, Del Vecchio L: Corticosteroids in patients with IgA nephropathy and severe chronic renal damage. Case Rep Nephrol 2012: 180691, 2012
14. Pozzi C, Del Vecchio L, Locatelli F: Can immunosuppressive therapy be useful in IgA nephropathy when the 'Point of No Return' has already been exceeded? Nephron 92: 699-701, 2002
15. Ballardie FW, Roberts IS: Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am SocNephrol 13: 142-148, 2002
16. Mitsuiki K, Harada A, Okura T, Higaki J: Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide. Clin Exp Nephrol 11: 297-303, 2007
17. Stangou M, Ekonomidou D, Giamalis P, Liakou H, Tsiantoulas A, Pantzaki A, Papagianni A, Efstratiadis G, Alexopoulos E, Memmos D: Steroids and azathioprine in the treatment of IgA nephropathy. Clin Exp Nephrol 15: 373-380, 2011
18. Pozzi C, Andrulli S, Pani A, Scaini P, RoccatelloD, FogazziG, Pecchini P, Rustichelli R, Finocchiaro P, Del Vecchio L, Locatelli F: IgA nephropathy with severe chronic renal failure: A randomized controlled trial of corticosteroids and azathioprine. J Nephrol 26: 86-93, 2013
19. Eitner F, Ackermann D, Hilgers RD, Floege J: Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: Rationale and study protocol. J Nephrol 21: 284-289, 2008
20. Coppo R: Is a legacy effect possible in IgA nephropathy? Nephrol Dial Transplant 28: 1657-1662, 2013
21. Tatematsu M, Yasuda Y, Morita Y, Sakamoto I, Kurata K, Naruse T, Yamamoto R, Tsuboi N, Sato W, Imai E, Matsuo S, Maruyama S: Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy. Clin Exp Nephrol 16: 883-891, 2012
22. Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D'Agati V, D'Amico G, Emancipator S, Emma F, Feehally J, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society: TheOxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility. Kidney Int 76: 546-556, 2009
23. Shoji T, Nakanishi I, Suzuki A, Hayashi T, Togawa M, Okada N, Imai E, Hori M, Tsubakihara Y: Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis 35: 194-201, 2000
24. Hotta O, Furuta T, Chiba S, Tomioka S, Taguma Y: Regression of IgA nephropathy: A repeat biopsy study. Am J Kidney Dis 39: 493-502, 2002
25. Stuart EA, Lee BK, Leacy FP: Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J Clin Epidemiol 66[Suppl]: S84-S90.e1, 2013
26. Tumlin JA, Hennigar RA: Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. Semin Nephrol 24: 256-268, 2004
27. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461-470, 1999
28. Miller WG: Estimating equations for glomerular filtration rate in children: Laboratory considerations. Clin Chem 55: 402-403, 2009
29. Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Cook HT, Feehally J, Roberts IS, Amore A, Alpers CE, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator SN, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo AB, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH,Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society: The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int 77: 921-927, 2010
30. Wühl E, Witte K, Soergel M, Mehls O, Schaefer F; German Working Group on Pediatric Hypertension: Distribution of 24-h ambulatory blood pressure in children: Normalized reference values and role of body dimensions. J Hypertens 20: 1995-2007, 2002
31. Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V: Principles for modeling propensity scores in medical research: A systematic literature review. Pharmacoepidemiol Drug Saf 13: 841-853, 2004